Metabolic disease as a risk of hepatocellular carcinoma

키워드

참고문헌 (22)

1. Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma: new trends", J Hepatol, 72, pp.250~261 (2020)
2. Ibrahim A. Hanouneh, "Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?", Clinical and Molecular Hepatology, 25(3), pp.264~269 (2019), 대한간학회
3. Nahon P, "Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications", Gastroenterology, 152, pp.142~156.e2 (2017)
4. Won Sohn, "Obesity and the risk of primary liver cancer: A systematic review and meta-analysis", Clinical and Molecular Hepatology, 27(1), pp.157~174 (2021), 대한간학회[DOI]
5. Shoelson SE, "Inflammation and insulin resistance", J Clin Invest, 116, pp.1793~1801 (2006)
6. Iyengar NM, "Obesity and cancer mechanisms: tumor microenvironment and inflammation", J Clin Oncol, 34, pp.4270~4276 (2016)
7. Han MS, "JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation", Science, 339, pp.218~222 (2013)
8. Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회
9. Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest", Nature, 444, pp.1027~1031 (2006)
10. Henao-Mejia J, "Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity", Nature, 482, pp.179~185 (2012)
11. oshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
12. Loo TM, "Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity", Cancer Discov, 7, pp.522~538 (2017)
13. Lu Y, "Yin Yang 1promotes hepatic steatosis through repression of farnesoid X receptor in obese mice", Gut, 63, pp.170~178 (2014)
14. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
15. Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
16. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
17. Gellert-Kristensen H, "Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population", Hepatology, 72, pp.845~856 (2020)
18. Martínez-Chantar ML, "Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice", Hepatology, 47, pp.1191~1199 (2008)
19. Liu Y, "Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2diabetes", J Clin Invest, 130, pp.2992~3004 (2020)
20. de Conti A, "MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis", Oncotarget, 8, pp.88517~88528 (2017)
21. Nishida N, "Immune checkpoint blockade for the treatment of human hepatocellular carcinoma", Hepatol Res, 48, pp.622~634 (2018)
22. Ringelhan M, "The immunology of hepatocellular carcinoma", Nat Immunol, 19, pp.222~232 (2018)